Title: FDA Approves Lower-Cost Daily Weight Loss Pill from Eli Lilly - A Breakthrough in Obesity Treatment?
The Food and Drug Administration (FDA) has recently approved a new weight loss pill called Foundayo, developed by drugmaker Eli Lilly. This daily oral medication is the second GLP-1 receptor agonist to hit the market after Novo Nordisk's Wegovy pill in December last year. The approval of this lower-cost alternative comes as a relief for those seeking effective weight loss solutions without breaking the bank.
Foundayo will be available in six doses, with patients starting on the lowest dose and gradually increasing it to minimize side effects. Unlike its counterpart Wegovy, Foundayo can be taken at any time of day without strict meal restrictions. The lowest dose is expected to cost around $149 per month for those paying out-of-pocket, while higher doses may reach up to $349 monthly. It remains uncertain how many private insurers will cover the drug; however, under a Trump administration plan, Medicare could potentially start covering it as early as this summer with copays ranging from $50 per month.
Eli Lilly CEO Dave Ricks hailed Foundayo as "a breakthrough in that it's a simple oral medication," adding that users can easily incorporate it into their daily routine by placing the pill in its case each morning. The approval of this drug marks another milestone in the expanding GLP-1 market, which offers various options for weight loss, different forms, and potentially lower prices.
Lilly also has another GLP-1 drug in development called retatrutide, which has shown greater weight loss results than any other drug on the market during trials. However, pill versions generally lead to less significant weight loss compared to weekly injections - a factor that might make them less appealing for some patients.
Phase 3 clinical trial data revealed that Foundayo helped users lose an average of 12.4% of their body weight at its highest dose after 72 weeks, similar to Wegovy but slightly lower than injectable versions of both Wegovy and Zepbound. Despite this slight difference in effectiveness, the approval of Foundayo represents a significant step forward in obesity treatment options available today.
In conclusion, the FDA's approval of Eli Lilly's Foundayo marks an exciting development in the fight against obesity. With its lower cost and convenient daily dosing regimen, this oral GLP-1 receptor agonist offers hope to many who struggle with weight management issues. As more affordable options become available, we can expect increased accessibility and adoption of these life-changing treatments for those in need.
Source: [Original Article](https://www.nbcnews.com/health/health-news/foundayo-weight-loss-pill-fda-approves-eli-lilly-glp-1-cost-rcna265907) #approves
Check out my AI projects on <a href='https://huggingface.co/ghostail'>Hugging Face</a>, join our community on <a href='https://discord.com/invite/zgKZUJ6V8z'>Discord</a>, and explore my services at <a href='https://ghostai.pro'>GhostAI</a>!